Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Panion & Bf Biotech Inc. (1760.TW)
Taipei, TW
Panion & Bf Biotech Inc. is a biopharmaceutical firm operating in Taiwan, engaged in the production and distribution of a diverse range of pharmaceutical goods. Its offerings cater to several key therapeutic and wellness segments, including medical aesthetics, renal care, respiratory health, and gastrointestinal support. Beyond these, the company also provides oral medications, topical treatments, and an array of hygiene products like hand, mechanical, and skin disinfectants, alongside body lotions. Additionally, Panion & Bf Biotech supplies veterinary health solutions, notably surgical and dermatological prescriptions for animals. Established in 1976, the company maintains its corporate headquarters in Taipei, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.65% | -5.88% | -5.74% | -3.80% | -8.30% | -3.49% | -20.63% | -57.33% | -38.61% | -76.17% | +226.88% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+1.7% ★ Q1'26: +7.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+53.1% ★ Q1'26: +81.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+9.1% Q1'26: +3.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+14.9% ★ Q1'26: +16.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+9.3% ★ Q1'26: +10.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.2% ★ Q1'26: +0.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.45× Q1'26: 1.87× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.21B
est: 1.20B (+0.9%)
|
1.41B
est: 1.41B (+0.1%)
|
1.57B
est: 1.60B (-1.6%)
|
1.57B
est: 1.67B (-6.0%)
|
1.90B
est: 1.92B (-0.9%)
|
2.40B
est: 2.69B (-10.8%)
|
1.88B
est: 2.01B (-6.3%)
|
2.03B
est: 2.06B (-1.6%)
|
2.06B
est: 2.06B (+0.1%)
|
2.17B
2.17B – 2.17B
+5.4% YoY
|
| EBITDA |
186.32M
est: 211.58M (-11.9%)
|
253.74M
est: 247.83M (+2.4%)
|
296.48M
est: 281.62M (+5.3%)
|
181.46M
est: 293.68M (-38.2%)
|
343.05M
est: 337.54M (+1.6%)
|
504.62M
est: 473.48M (+6.6%)
|
327.22M
est: 394.07M (-17.0%)
|
405.32M
est: 404.62M (+0.2%)
|
446.27M
est: 404.23M (+10.4%)
|
426.20M
426.20M – 426.20M
+5.4% YoY
|
| EBIT |
143.26M
est: 122.89M (+16.6%)
|
244.44M
est: 143.94M (+69.8%)
|
228.12M
est: 163.57M (+39.5%)
|
93.87M
est: 170.57M (-45.0%)
|
197.33M
est: 196.04M (+0.7%)
|
340.99M
est: 275.00M (+24.0%)
|
194.08M
est: 240.42M (-19.3%)
|
240.89M
est: 246.86M (-2.4%)
|
307.85M
est: 246.62M (+24.8%)
|
260.02M
260.02M – 260.02M
+5.4% YoY
|
| Net Income |
90.54M
est: 131.48M (-31.1%)
|
159.17M
est: 137.82M (+15.5%)
|
161.33M
est: 232.10M (-30.5%)
|
27.90M
est: 51.15M (-45.5%)
|
104.40M
est: 205.33M (-49.2%)
|
182.35M
est: 410.56M (-55.6%)
|
77.22M
est: 101.18M (-23.7%)
|
124.52M
est: 128.49M (-3.1%)
|
190.17M
est: 193.60M (-1.8%)
|
215.01M
215.01M – 215.01M
+11.1% YoY
|
| SGA |
446.02M
est: 375.92M (+18.6%)
|
470.52M
est: 440.32M (+6.9%)
|
517.44M
est: 500.36M (+3.4%)
|
560.16M
est: 521.78M (+7.4%)
|
587.00M
est: 599.70M (-2.1%)
|
656.06M
est: 841.23M (-22.0%)
|
601.58M
est: 594.77M (+1.1%)
|
618.22M
est: 610.70M (+1.2%)
|
564.55M
est: 610.11M (-7.5%)
|
643.26M
643.26M – 643.26M
+5.4% YoY
|
| EPS |
1.31
est: 1.53 (-14.5%)
|
2.06
est: 1.61 (+28.2%)
|
2.07
est: 2.71 (-23.5%)
|
0.36
est: 0.60 (-39.6%)
|
1.32
est: 2.39 (-44.8%)
|
2.13
est: 4.79 (-55.5%)
|
0.90
est: 1.18 (-23.8%)
|
1.45
est: 1.50 (-3.3%)
|
2.22
est: 2.26 (-1.8%)
|
2.51
2.51 – 2.51
+11.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 103.5K | 0.65% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 412.2K | 0.06% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 140.8K | 0.39% |
| 4 | Vanguard ESG International Stock ETF VSGX | 0.00% | 100.3K | 0.10% |
| 5 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 21.5K | 0.46% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 13.0K | 0.48% |
| 7 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 29.3K | 0.26% |
| 8 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.45M | 0.06% |
| 9 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 37.1K | 0.29% |
| 10 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 44.8K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Feng-Jen Wang | Financial Director | — | — |
| Ken Chian | Associate Director of Innovative Diagnostics Division | — | — |
| Mei-Lun Chiu | Accounting Supervisor | — | — |
| Nick Tsai | Deputy GM & Spokesperson of the Operations Management Department | — | — |
| Raymond Chuang | Associate Director of Innovative Healthcare Division | — | — |
| Tsung-Ming Chiang | GM & Director | — | male |
| Zong Huai Lu | Deputy General Manager | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1760.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
